Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LYT-500
- Development stage
- Preclinical
- Lead developer
- PureTech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LYT-500 is an orally administered therapeutic candidate in development for the treatment of inflammatory bowel disease (IBD), specifically targeting mucosal barrier damage. It is a novel combination drug that contains interleukin 22 (IL-22) and an anti-inflammatory small molecule, designed to address two key underlying causes of IBD pathogenesis and progression: mucosal barrier disruption and inflammation. The dual mechanism aims to provide both mucosal repair via IL-22 agonism and targeted resolution of tissue inflammation through the immunosuppressant component. Developed using technology from Alivio Therapeutics, now part of PureTech, this approach seeks to maximize efficacy at inflamed sites while minimizing systemic exposure and toxicity compared to existing biologic therapies[1][2][4][7].
- Brand names
- LYT-500LYT500LYT 500
- Other names
- LYT-500LYT500LYT 500
02
Targets
IL-22R (Interleukin 22 Receptor)
Beyond the preview
Go deeper on LYT-500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYT-500.